The Phase-2 trial of gemcitabine, cisplatin plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer had interesting preliminary results. Prof. Galsky shares them with us in this interview.
The Phase-2 trial of gemcitabine, cisplatin plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer had interesting preliminary results. Prof. Galsky shares them with us in this interview.